URL copied
Covishield produces more antibodies with higher seropositivity rate than Covaxin
A preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) has stated Covishield vaccine produced more antibodies than Covaxin. The study, involving healthcare workers (HCW) who have received both doses of either of the two vaccines, also said seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients as compared to Covaxin after the first dose.
The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.
It said that both vaccines Covishield and Covaxin elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.